Bicycle Therapeutics PLC
BCYC
查看详细走势图
7.020USD
-0.170-2.36%
交易中 （美东）报价延迟15分钟
350.08M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.36%
5天
-4.23%
1月
+11.08%
6月
-5.39%
今年开始到现在
-49.86%
1年
-52.18%
查看详细走势图
TradingKey Bicycle Therapeutics PLC股票评分
单位: USD 更新时间: 2025-12-22操作建议
Bicycle Therapeutics PLC当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名54/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价21.58。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Bicycle Therapeutics PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
14
位分析师
买入
评级
21.583
目标均价
+191.67%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Bicycle Therapeutics PLC亮点
亮点风险
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
业绩高增长
公司营业收入稳步增长，连续3年增长143.90%
业绩增长期
公司处于发展阶段，最新年度总收入35.27M美元
利润高增长
公司净利润处于行业前列，最新年度总收入35.27M美元
估值高估
公司最新PE估值-1.98，处于3年历史高位
机构加仓
最新机构持股39.22M股，环比增加0.08%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值9.37K
Bicycle Therapeutics PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Bicycle Therapeutics PLC简介
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
公司代码BCYC
公司Bicycle Therapeutics PLC
CEOLee (Kevin)
网址https://www.bicycletherapeutics.com/
常见问题
Bicycle Therapeutics PLC(BCYC)的当前股价是多少？
Bicycle Therapeutics PLC(BCYC)的当前股价是 7.020。
Bicycle Therapeutics PLC的股票代码是什么？
Bicycle Therapeutics PLC的股票代码是BCYC。
Bicycle Therapeutics PLC股票的52周最高点是多少？
Bicycle Therapeutics PLC股票的52周最高点是15.470。
Bicycle Therapeutics PLC股票的52周最低点是多少？
Bicycle Therapeutics PLC股票的52周最低点是6.030。
Bicycle Therapeutics PLC的市值是多少？
Bicycle Therapeutics PLC的市值是350.08M。
Bicycle Therapeutics PLC的净利润是多少？
Bicycle Therapeutics PLC的净利润为-169.03M。
现在Bicycle Therapeutics PLC(BCYC)的股票是买入、持有还是卖出？
根据分析师评级，Bicycle Therapeutics PLC(BCYC)的总体评级为买入，目标价格为21.583。
Bicycle Therapeutics PLC(BCYC)股票的每股收益（EPS TTM）是多少
Bicycle Therapeutics PLC(BCYC)股票的每股收益（EPS TTM）是-3.627。
相关品种
